“By 2016, six out of ten of the blockbusters will be monoclonal-antibody-based therapeutics. With patent protection ending on many of these blockbusters by 2020 and this market estimated to be ...

Nicole Kavanaugh Manager, Downstream Process Development Catalent Biologics. Nicole Kavanaugh manages a team of scientists in Catalent Madison’s Downstream Process Development Department. Her group is ...

A novel continuous monoclonal antibody (mAb) production process could help drug firms reach quality goals and cope with changing capacity needs, according to CDMO Fujifilm Diosynth Biotechnologies ...

ArgusEye, announced the introduction of the AugaOne™ sensor system. AugaOne is the first product in the Company’s sensor system platform, Auga™, and is tailored to accelerate downstream monoclonal ...